Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ PRE 14A Other preliminary proxy statements Accession Number: 0001047469-20-003566 Act: 34 Size: 1 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069178 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069179 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069180 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069182 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069184 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-069188 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001047469-20-003282 Act: 33 Size: 549 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-20-067962 Act: 34 Size: 415 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001047469-20-003278 Act: 33 Size: 552 KB 网页链接